In Brief: FDA proposed CGMP amendments
This article was originally published in The Tan Sheet
FDA proposed CGMP amendments: FDA indicates that it will extend the comment period for proposed amendments to the CGMP regulations for pharmaceuticals by 60 or 90 days in response to requests from industry. PhRMA and Perrigo asked the agency for additional time to comment on the proposal, published in the May 3 Federal Register, which would clarify certain manufacturing, quality control and documentation requirements, ensure that the regs more accurately encompass CGMP and update the process and methods validation requirements to incorporate previously issued guidance and current practice. The current deadline for written comments is Aug. 1...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC